Confirmation that AKBA PR was pretty misleading - Fresenius in US not bound to use AKBA drug in any way:
$FGEN BL: $AKBA did not sign an exclusive deal with Fresenius as they cannot with a hospital. 100% of market will go to $FGEN as they r FTM. pic.twitter.com/XjTFsNn0xA
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.